Rheonova offers a new physical biomarker for drug discovery and efficacy evaluation. Our product Rheomuco and the associated services aim to provide new pharmacodynamic data during in vitro studies or clinical trials in the fields of pulmonary diseases (cystic fibrosis, COPD, asthma…). Our technology measures the viscoelasticity of mucus and deliver the physical properties of bronchial secretions. The benchmark of new molecules is performed using patient sputum or mucus obtained by cell culture.